ELIQUENT Life Sciences Announces Strategic Acquisition of Leading Pharmacovigilance Firm Truliant Consulting & Expanded Pharmacovigilance Platform
ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting (Truliant), a leading pharmacovigilance, risk management, and regulatory compliance advisory firm. This strategic acquisition reinforces ELIQUENT’s position as a premier provider of end-to-end support for every stage of the product lifecycle.
“Truliant has built a reputation for delivering high-quality pharmacovigilance and risk management solutions. Truliant’s specialized knowledge, technology-driven approach, and operational scalability will expand ELIQUENT’s pharmacovigilance platform to offer clients a premier partner for regulatory success,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
Today’s announcement follows ELIQUENT’s recent appointment of globally recognized pharmacovigilance leader, Shelley Gandhi. With more than three decades of risk management expertise, Gandhi’s firsthand knowledge of regulatory expectations is invaluable to companies navigating complex safety assessments and reporting challenges. ELIQUENT’s acquisition of Truliant, combined with the addition of Gandhi, underscores the firm’s commitment to building a world-class pharmacovigilance platform by combining top industry expertise with cutting-edge technology and scalable solutions to better serve global life science innovators.
“Since our founding, Truliant has delivered high-impact pharmacovigilance and risk management consulting to clients worldwide. Joining ELIQUENT Life Sciences marks an exciting new chapter - one where we will expand our pharmacovigilance expertise within a team that brings complementary strengths. We are fully aligned with ELIQUENT’s vision and look forward to driving innovation through this collaboration,” said Jamie Portnoff, CEO and Co-Founder, Truliant Consulting.
The integration of Truliant’s tailored, technology-driven service offerings expands ELIQUENT’s pharmacovigilance platform to provide an even broader range of solutions across processes optimization, integration of cutting-edge technologies, and ability to build scalable pharmacovigilance programs. The combined capabilities deliver a full-spectrum of strategic and operational tools, expertise, and technology and empower clients to manage risk and maintain compliance in the following areas:
- Risk Management: Proactive strategies to identify, assess, and mitigate safety risks—aligned with global regulatory expectations.
- Operational Efficiency: Streamlined processes and scalable workflows that reduce complexity and boost performance.
- Compliance Readiness: End-to-end support to ensure inspection readiness and alignment with global regulators.
- Safety Oversight: Robust governance and scientific leadership to maintain product safety and ensure regulatory accountability.
- Technology Integration: Expert guidance in selecting, implementing, and optimizing pharmacovigilance systems for seamless, compliant operations.
- Scalable Solutions: Flexible support models that grow with your business—ensuring the right expertise, at the right time.
Truliant Consulting was advised by Sullivan and Worcester. ELIQUENT and GHO Capital were advised by Ropes & Gray LLP.
About Truliant
Founded in 2021 and headquartered in Baltimore, Maryland, Truliant Consulting is a women-owned business specializing in pharmacovigilance and risk management consulting for the life sciences industry. Truliant's team is comprised of experienced professionals with deep domain knowledge and a commitment to delivering innovative, efficient, and compliant solutions.
About ELIQUENT
ELIQUENT Life Sciences is a leading global consulting group delivering regulatory affairs, pharmacovigilance, quality, and compliance solutions that support clients across therapeutic modalities, phase-based pathways, and major global markets. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to bring new therapies to gain and maintain market authorization for their products. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
Learn more about ELIQUENT Life Sciences at eliquent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402557387/en/
Contacts
Taryn Fritz Walpole
twalpole@eliquent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The World's Smallest PPG Sensor Head3.4.2025 14:29:00 EEST | Press release
SCIVAX Corporation (Headquarters: Kawasaki Japan, President: Satoru Tanaka, hereinafter referred to as "SCIVAX") and TSLC Corporation, a SemiLEDs Corporation (NASDAQ:LEDS a Delaware company listed in the NASDAQ exchange) wholly owned company announced that SCIVAX+TSLC have developed the world's smallest PPG (PhotoPlethysmoGraphy)* sensor head, which will be presented at the display related technology exhibition ”Touch Taiwan” to be held in Taipei, Taiwan from April 16 to 18, 2025. The samples of the PPG sensor head for evaluation will begin in April 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402019875/en/ World's smallest PPG Sensor Head To date, SCIVAX and TSLC have developed the world's smallest light source device, Amtelus®, by combining our partner’s material technology with SCIVAX's optical lens design technology and TSLC’s advanced packaging technology and have begun shipping samples for evaluation. Utiliz
FlexTrade First Provider to Offer Goldman Sachs Order Status Updates via API3.4.2025 13:02:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, has today announced that Goldman Sachs' real-time Order Status Updates (OSUs) for algorithmic orders can be streamed directly into FlexTrade’s OEMS Order Blotter via a new proprietary API – fundamentally changing how Goldman Sachs delivers data to buy-side clients. The announcement is part of Goldman Sachs’ new suite of real-time alerting and data analytics offering, GS Alerts, which is aimed at providing clients with seamless access to metrics from within their EMS/OMS blotter. The new OSUs package offers metrics for orders in developed and emerging markets in EMEA equities, including expected residuals, estimated quantity reserved for the close, and the average participation rate of the order. Using a new API to deliver OSU data, rather than FIX, opens new possibilities regarding the frequency and type of data being delivered to FlexTrade clients, eliminating unnecessary overheads c
Articy Software launches articy:draft X on Mac OS – A New Era for Narrative Design3.4.2025 13:00:00 EEST | Press release
No longer a Windows-exclusive tool, articy:draft X , the leading narrative design software, is now officially available on Mac OS. This highly anticipated release marks a significant milestone in Articy's journey, opening doors for a new wave of creators and storytellers who have been eager to harness its powerful features on their preferred platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250403045197/en/ articy:draft X has become a cornerstone for narrative designers, game developers, and storytellers worldwide, providing a robust set of tools for interactive story creation, complex dialogue structuring, scripting, and seamless world-building complete with localization, voice over and dedicated engine exports. With its launch on Mac OS, the software is now accessible to an even broader community, empowering creators to design captivating stories and intricate game worlds, regardless of the operating system. Bringin
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program3.4.2025 13:00:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to terminate the trial. “We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are m
BearingPoint client success story: Driving digital continuity in product development through a data management hub3.4.2025 12:08:00 EEST | Press release
As vehicle development becomes increasingly complex with the transition to electromobility and the integration of software across almost all components, seamless coordination among specialized departments involved is more critical than ever. At the same time, competitive pressures demand shorter development cycles, making traditional methods of data exchange, such as point-to-point interfaces or manual processes, less efficient and prone to inconsistencies. However, a high level of data consistency is essential to ensure smooth development, integration, and validation, particularly in the development of electric control units and onboard communication systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250403719346/en/ BearingPoint is supporting BMW Group in establishing a central data hub to create a high-quality data foundation for the electrical/electronics (E/E) development process to enable cross-departmental digita
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom